ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Tumor necrosis factor (TNF)"

  • Abstract Number: 1016 • ACR Convergence 2021

    Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice

    Kiana Chen1, Xi Lin1, Lianping Xing2, H. Mark Kenney3, Richard Bell4, Edward Schwarz5 and Homaira Rahimi5, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester Medical Center, Webster, NY, 3University of Rochester Medical Center, Rochester, NY, 4Hospital for Special Surgery, New York, NY, 5University of Rochester, Rochester, NY

    Background/Purpose: Recently, CD45−CD31−Podoplanin (PDPN)+ synovial fibroblast-like cells, termed pre-inflammatory mesenchymal (PRIME) cells were found to be differentially expressed and circulate in the blood of rheumatoid…
  • Abstract Number: 1219 • ACR Convergence 2021

    Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

    Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
  • Abstract Number: 1338 • ACR Convergence 2021

    Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study

    Philip Mease1, Atul Deodhar2, Joseph Merola3, Iain McInnes4, Deepak Assudani5, Rajan Bajracharya5, Jason Coarse6, Barbara Ink7 and Georg Schett8, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Raleigh, NC, 7UCB Celltech, Slough, UK, Slough, United Kingdom, 8Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-­17A, and has demonstrated clinical improvements in joint and skin outcomes…
  • Abstract Number: 1429 • ACR Convergence 2021

    ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases

    Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA

    Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
  • Abstract Number: 0041 • ACR Convergence 2021

    Vascularized ‘Synovium-on-a-Chip’ – A Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis

    Theresa Wampler Muskardin1, Chao Ma2, Benteng Ma2, Kayla Van Buren3, Timothy Niewold4 and Weiqiang Chen2, 1Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, 2New York University, New York, NY, 3Mnemo Therapeutics, New York, NY, 4Colton Center for Autoimmunity NYU School of Medicine, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a common multisystem inflammatory condition, affecting approximately 1% of the world population. The mechanisms underlying RA are still incompletely defined…
  • Abstract Number: 1855 • ACR Convergence 2021

    Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis

    Yoshinobu Koyama1, Yoshiharu Sato2, Tatsuma Shoji2, Soichiro Fuke1, Takatsune Umayahara1 and Moe Sakamoto1, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan

    Background/Purpose: Pulmonary hypertension (PH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of current…
  • Abstract Number: 0185 • ACR Convergence 2021

    Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

    Silke Roedder1, Emily Wendt2, Chad Burris2, Jonathan Nazareon2, Grace Park3, Phil Pangilinan2, Gianna Huang2, Anubhav Mathur2, James Taylor2, Andrew Billin2 and Franziska Matzkies4, 1Gilead Sciences, Menlo Park, CA, 2Gilead Sciences, Foster City, CA, 3Gilead Sciences, Seattle, WA, 4Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
  • Abstract Number: 1891 • ACR Convergence 2021

    Variable Effects of Testosterone on Male versus Female Derived Macrophages in Inflammatory Arthritis

    Kiana Chen1, Xi Lin1, Lianping Xing2, H. Mark Kenney3, Richard Bell4, Edward Schwarz5 and Homaira Rahimi5, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester Medical Center, Webster, NY, 3University of Rochester Medical Center, Rochester, NY, 4Hospital for Special Surgery, New York, NY, 5University of Rochester, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that is female predominant. The TNF-transgenic (TNF-Tg) mouse model of RA also develops a sexually…
  • Abstract Number: 0204 • ACR Convergence 2021

    Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents

    Soo Min Ahn1, Jonggi Choi2, Byong Duk Ye2, Suk-Kyun Yang2, Ji Seon Oh3, Yong-Gil Kim2, Chang-Keun Lee2, Bin Yoo1, Sang Hyoung Park2 and Seokchan Hong2, 1ASAN MEDICAL CENTER, Seoul, South Korea, 2Asan Medical Center, Seoul, Republic of Korea, 3Asan Medical Center, Ulsan, Republic of Korea

    Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However,…
  • Abstract Number: 0246 • ACR Convergence 2021

    Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs

    Betul Sozeri1, Kenan Barut2, Erdal Atalay3, Aysenur Pac Kisaarslan4, Semanur Ozdel5, Ozge Altug6, Ferhat Demir1, Balahan Makay7, Nuray Aktay Ayaz8, Ersen Acar9, Fatih Haslak2, Erdal Sag10, Mehmet YILDIZ2, Ummusen Kaya Akca10, Amra Adrovic2, Yelda Bilginer10, Hakan Poyrazoglu11, Erbil Unsal7, Ozgur Kasapcopur12 and Seza Ozen3, 1University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, 3Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey, 4Erciyes University Medical Faculty, Pediatric Rheumatology, Kayeri, Turkey, 5Ankara Dr.Sami Ulus Gynecology and Pediatrics Research and Training Hospital, Pediatric Rheumatology, Ankara, Turkey, 6Dr Behcet Uz Children's Hospital, Pediatric Rheumatology, Izmir, Turkey, 7Dokuz Eylul University Faculty of Medicine, Pediatric Rheumatology, Izmir, Turkey, 8Istanbul University, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, 9Novartis, Istanbul, Turkey, 10Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 11Erciyes University Faculty of Medicine, Pediatric Rheumatology, Kayseri, Turkey, 12Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is the most acute and severe form of JIA. Despite the substantial evidence supporting the effectiveness of biologic drugs…
  • Abstract Number: 0451 • ACR Convergence 2021

    Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort

    Murat Torgutalp1, Valeria Rios Rodriguez1, Maryna Verba2, Mikhail Protopopov1, Fabian Proft1, Judith Rademacher1, Hildrun Haibel3, Martin Rudwaleit4, Joachim Sieper3 and Denis Poddubnyy5, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 3Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 5Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Observational cohort studies have shown that there is low, but still detectable progression level in radiographic sacroiliitis, which might also have an impact on…
  • Abstract Number: 0507 • ACR Convergence 2020

    Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study

    Grace Wright1, Peter Nash2, Laura Coates3, Jordi Gratacós4, Frank Behrens5, Kevin Ding6, Weibin Bao7, Luminita Pricop6, Corine Gaillez8 and Iain McInnes9, 1Association of Women in Rheumatology, New York, NY, 2School of Medicine Griffith University, Brisbane, Queensland, Australia, 3University of Oxford, Oxford, United Kingdom, 4University Hospital Parc Tauli Sabadell, Barcelona, Spain, 5CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 6Novartis Pharmaceuticals Corporation, East Hanover, 7Novartis Pharmaceuticals Corporation, East Hannover, 8Novartis Pharma AG, Basel, Switzerland, 9Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
  • Abstract Number: 0573 • ACR Convergence 2020

    Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice

    Uta Kiltz1, Styliani Tsiami2, Xenofon Baraliakos1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: A single switch from an originator to a biosimilar product has been shown to be safe and effective in the treatment of rheumatic musculoskeletal…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • Abstract Number: 0873 • ACR Convergence 2020

    Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Charlie Lovan5 and Alexis Ogdie6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., North Chicago, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology